Charles Russell Speechlys advises Kreos Capital on its €15 million growth capital investment
Charles Russell Speechlys LLP advised Kreos Capital V (UK) Limited on its €15 million growth capital investment in Kiadis Pharma NV (“Kiadis Pharma”), a Dutch company listed on Euronext Amsterdam and Euronext Brussels.
Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders. Its product candidates have the potential to make allogeneic hematopoietic stem cell transplantations (HSCT) safer and more effective for patients.
Kiadis Pharma announced to the market that it will use the financing to advance the development of its ATIR products, for general corporate purposes and to repay €5.3 million of existing Dutch Government Loans.
The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Senior Associate) and Amelly Kok (Associate) from our Corporate Team. Fruytier Lawyers in Business advised on matters of Dutch law and Borden Ladner Gervais LLP on matters of Canadian law respectively.
News & Insights
Bad AGMs (and how to avoid them): January 2019
In case you missed it - we provide essential tips to help avoid those difficult AGMs that no one wants to experience from our mock AGM.
Malcolm MacDougall scoops top place in MergerMarket ranking for most active deal lawyer by volume 2018
The Mergermarket league tables are accumulated by deals announced in 2018, available on Mergermarket's deals database.
Charles Russell Speechlys advises Avora Ltd on a Series A funding round
Avora is a technology and software company providing business intelligence and machine learning services.